Quantcast

KEYTRUDA® (pembrolizumab) plus LENVIMA® (lenvatinib) Combination Demonstrated Clinically Meaningful Tumor Response Rates in Unresectable Hepatocellular Carcinoma and Advanced Renal Cell Carcinoma

Analyses from KEYTRUDA Plus LENVIMA Trials to be Presented at 2020 ASCO Annual Meeting KENILWORTH, N.J. & WOODCLIFF LAKE, N.J.–(BUSINESS

Read more

Roche initiates phase III clinical trial of Actemra/RoActemra plus remdesivir in hospitalised patients with severe COVID-19 pneumonia

Roche is also close to completing enrolment of a global randomised, double-blind, placebo-controlled phase III clinical trial of Actemra®/RoActemra® (tocilizumab) in hospitalised patients with severe COVID-19 pneumonia (COVACTA), with results expected this summer.

Read more